SWEDISH ORPHAN/S (OTCMKTS:SWTUY – Get Free Report) and William Hill (OTCMKTS:WIMHY – Get Free Report) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk and valuation.
Earnings & Valuation
This table compares SWEDISH ORPHAN/S and William Hill’s gross revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
SWEDISH ORPHAN/S | $763.19 million | 8.71 | $134.73 million | $0.50 | 48.76 |
William Hill | $1.58 billion | 2.49 | -$34.35 million | $0.54 | 27.78 |
SWEDISH ORPHAN/S has higher earnings, but lower revenue than William Hill. William Hill is trading at a lower price-to-earnings ratio than SWEDISH ORPHAN/S, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Analyst Ratings
This is a summary of recent ratings and target prices for SWEDISH ORPHAN/S and William Hill, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
SWEDISH ORPHAN/S | 0 | 0 | 0 | 0 | N/A |
William Hill | 0 | 0 | 0 | 0 | N/A |
Profitability
This table compares SWEDISH ORPHAN/S and William Hill’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
SWEDISH ORPHAN/S | 25.75% | 29.63% | 18.74% |
William Hill | N/A | N/A | N/A |
Summary
SWEDISH ORPHAN/S beats William Hill on 6 of the 9 factors compared between the two stocks.
About SWEDISH ORPHAN/S
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetic and lysosomal diseases. The company offers Elocta to treat haemophilia A; and Alprolix to treat haemophilia B. It also provides Orfadin for the treatment of hereditary tyrosinaemia type 1; and Kineret for the treatment of auto inflammatory condition, as well as Xiapex to treat Dupuytren's contracture and Peyronie's disease. In addition, the company manufactures drug substance for ReFacto AF; and develops BIVV001 and BIVV002 for the treatment of hemophilia. It operates in Sweden, the Middle East, North Africa, Russia, North America, other European countries, and internationally. The company has an agreement with Bioverativ for the development and commercialization of Elocta and Alprolix, as well as XTEN-programs. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.
About William Hill
William Hill PLC, a sports betting and gaming company, provides sports betting and gaming services in the United Kingdom, the United States, and internationally. It operates through retail, online, and US segments. The company operates licensed betting offices (LBOs) that offers sports betting services on horse racing, football, greyhounds, and other sports, as well as gaming machines. It also provides online sports betting, casino, poker, and other gaming products, as well as telephone betting services. William Hill PLC was formerly known as William Hill Limited and changed its name to William Hill PLC in May 2002. The company was founded in 1934 and is based in London, United Kingdom. As of April 22, 2021, William Hill PLC operates as a subsidiary of Caesars Entertainment, Inc.
Receive News & Ratings for SWEDISH ORPHAN/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SWEDISH ORPHAN/S and related companies with MarketBeat.com's FREE daily email newsletter.